Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause diseases.
Youngen has been dedicated to bringing RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-class and best-in-class potentials.
We're exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.
Youngen is a subsidiary of Beijing Hotgen Biotech Co., Ltd. (SSE:688068). Holding a strong presence in in-vitro diagnostics market, Hotgen is also dedicated to biopharmaceutical industry, continuously empowering its subsidiaries in this direction.
Youngen has formed three major technology platforms in extrahepatic targeted delivery, chemical modification, and target selection, established intellectual property protections.
Youngen has an excellent Chief Scientist and a team with rich experience in nucleic acid chemistry, drug discovery, pharmacology.
Youngen has strong independent clinical development capabilities, with an experienced global clinical development and medical affairs team.
